Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.

A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.

The company’s CD38 x CD28 MAb is among recent clinical trial entrants.

October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.

RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.

AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.

A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.

Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.

It’s back to school for biotech, with a packed conference schedule.